{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:12:32Z","timestamp":1788174752216,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10840-021-00958-4","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:05:57Z","timestamp":1613145957000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes in patients implanted with a Watchman device in relation to choice of anticoagulation and indication for implant"],"prefix":"10.1007","volume":"64","author":[{"given":"Muhammad","family":"Ajmal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew D.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-4746","authenticated-orcid":false,"given":"Julia H.","family":"Indik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"issue":"6","key":"958_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","volume":"127","author":"VY Reddy","year":"2013","unstructured":"Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013;127(6):720\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.114389.","journal-title":"Circulation."},{"issue":"1","key":"958_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","volume":"64","author":"DR Holmes Jr","year":"2014","unstructured":"Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2014.04.029.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"958_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","volume":"123","author":"VY Reddy","year":"2011","unstructured":"Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011;123(4):417\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.976449.","journal-title":"Circulation."},{"key":"958_CR4","unstructured":"Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology (CAP2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01760291. Accessed January 9, 2021."},{"key":"958_CR5","unstructured":"Decision Memo for Percutaneous Left Atrial Appendage Closure (LAA) Closure Therapy (CAG-00445N). https:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?NCAId=281&bc=AAAAAAAAQAAA&%20. Accesssed: January 9, 2021."},{"issue":"13","key":"958_CR6","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2019.12.040","volume":"75","author":"JV Freeman","year":"2020","unstructured":"Freeman JV, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, et al. The NCDR Left Atrial Appendage Occlusion Registry. J Am Coll Cardiol. 2020;75(13):1503\u201318. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.040.","journal-title":"J Am Coll Cardiol"},{"key":"958_CR7","doi-asserted-by":"publisher","unstructured":"Katz DF, Maddox TM, Turakhia M, Gehi A, O'Brien EC, Lubitz SA, et al. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. Circ Cardiovasc Qual Outcomes. 2017;10(5). https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.116.003476.","DOI":"10.1161\/CIRCOUTCOMES.116.003476"},{"issue":"17","key":"958_CR8","doi-asserted-by":"publisher","first-page":"e012646","DOI":"10.1161\/JAHA.119.012646","volume":"8","author":"AJ Rose","year":"2019","unstructured":"Rose AJ, Goldberg R, McManus DD, Kapoor A, Wang V, Liu W, et al. Anticoagulant prescribing for non-valvular atrial fibrillation in the Veterans Health Administration. J Am Heart Assoc. 2019;8(17):e012646. https:\/\/doi.org\/10.1161\/JAHA.119.012646.","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"958_CR9","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","volume":"75","author":"P Osmancik","year":"2020","unstructured":"Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75(25):3122\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.067.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"958_CR10","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","volume":"61","author":"VY Reddy","year":"2013","unstructured":"Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2013.03.035.","journal-title":"J Am Coll Cardiol"},{"key":"958_CR11","unstructured":"Assessment of the WATCHMAN device in patients unsuitable for oral anticoagulation (ASAP-TOO). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02928497. Accessed January 9, 2021."},{"issue":"11","key":"958_CR12","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119\u201326. https:\/\/doi.org\/10.1111\/jth.13140.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"958_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/clc.22478","volume":"38","author":"LI Bosche","year":"2015","unstructured":"Bosche LI, Afshari F, Schone D, Ewers A, Mugge A, Gotzmann M. Initial experience with novel oral anticoagulants during the first 45 days after left atrial appendage closure with the Watchman device. Clin Cardiol. 2015;38(12):720\u20134. https:\/\/doi.org\/10.1002\/clc.22478.","journal-title":"Clin Cardiol"},{"issue":"4","key":"958_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.21037\/atm.2019.12.116","volume":"8","author":"ZC Gu","year":"2020","unstructured":"Gu ZC, Qiao ZQ, Hao ZY, Li Z, Jiang LS, Ge H, et al. Initial anticoagulation experience with standard-dose rivaroxaban after Watchman left atrial appendage occlusion. Ann Transl Med. 2020;8(4):105. https:\/\/doi.org\/10.21037\/atm.2019.12.116.","journal-title":"Ann Transl Med"},{"issue":"1","key":"958_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hrthm.2016.10.020","volume":"14","author":"Y Enomoto","year":"2017","unstructured":"Enomoto Y, Gadiyaram VK, Gianni C, Horton RP, Trivedi C, Mohanty S, et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm. 2017;14(1):19\u201324. https:\/\/doi.org\/10.1016\/j.hrthm.2016.10.020.","journal-title":"Heart Rhythm"},{"issue":"24","key":"958_CR16","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","volume":"70","author":"VY Reddy","year":"2017","unstructured":"Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70(24):2964\u201375. https:\/\/doi.org\/10.1016\/j.jacc.2017.10.021.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"958_CR17","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jcin.2015.08.035","volume":"8","author":"MJ Price","year":"2015","unstructured":"Price MJ, Reddy VY, Valderrabano M, Halperin JL, Gibson DN, Gordon N, et al. Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience. JACC Cardiovasc Interv. 2015;8(15):1925\u201332. https:\/\/doi.org\/10.1016\/j.jcin.2015.08.035.","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"958_CR18","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"10","key":"958_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"22","key":"958_CR20","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"issue":"11","key":"958_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"9","key":"958_CR22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","volume":"138","author":"SR Dukkipati","year":"2018","unstructured":"Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN, et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138(9):874\u201385. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035090.","journal-title":"Circulation."},{"issue":"5 Pt A","key":"958_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.hrthm.2019.12.004","volume":"17","author":"S Staubach","year":"2020","unstructured":"Staubach S, Schlatterbeck L, Mortl M, Strohm H, Hoppmann P, Laugwitz KL, et al. Long-term transesophageal echocardiography follow-up after percutaneous left atrial appendage closure. Heart Rhythm. 2020;17(5 Pt A):728\u201333. https:\/\/doi.org\/10.1016\/j.hrthm.2019.12.004.","journal-title":"Heart Rhythm"},{"issue":"4","key":"958_CR24","doi-asserted-by":"publisher","first-page":"e006841","DOI":"10.1161\/CIRCEP.118.006841","volume":"12","author":"LV Boersma","year":"2019","unstructured":"Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage. Circ Arrhythm Electrophysiol. 2019;12(4):e006841. https:\/\/doi.org\/10.1161\/CIRCEP.118.006841.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"958_CR25","unstructured":"Comparison of anticoagulation with left atrial appendage closure after AF ablation (OPTION). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03795298?term=NCT03795298&draw=2&rank=1. Accessed January 9, 2021."},{"key":"958_CR26","unstructured":"WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement (WATCH-TAVR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03173534?cond=tavr+and+watchman&draw=2&rank=1. Accessed January 9, 2021."},{"key":"958_CR27","unstructured":"Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonists (CATALYST). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04226547?term=NCT04226547&draw=2&rank=1. Accessed January 9, 2021."},{"key":"958_CR28","unstructured":"WATCHMAN FLX in the OPTION and in the WATCHMAN FLX versus NOAC for Embolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation (CHAMPION-AF). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04394546?cond=CHAMPION-AF&draw=2&rank=1. Accessed January 9, 2021."}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-021-00958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-021-00958-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-021-00958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T06:08:34Z","timestamp":1656310114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-021-00958-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1007\/s10840-021-00958-4","relation":{},"ISSN":["1383-875X","1572-8595"],"issn-type":[{"value":"1383-875X","type":"print"},{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"12 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Institutional Review Board of St Joseph\u2019s Hospital and Medical Center prior to data collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}